chronic kidney disease

News

AZ drops two trials aimed at expanding Lokelma’s label

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea

News

Drug combos from AZ, Boehringer show promise in CKD

Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising

News

Bayer launches support tool for diabetic kidney disease

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression t

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

AZ drops two trials aimed at expanding Lokelma’s label

Drug combos from AZ, Boehringer show promise in CKD

Bayer launches support tool for diabetic kidney disease

Novo Nordisk’s semaglutide aces another outcomes trial

Jardiance cleared in EU for CKD, challenging Forxiga

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

chronic kidney disease

Editor's Picks